AbbVie’s Allergan reportedly files lawsuits over proposed generic Viberzi
MSN Labs and Sun Pharmaceutical are the only remaining defendants in a related consolidated case.
AbbVie’s Allergan unit reportedly has filed lawsuits alleging generic versions of its Viberzi proposed by MSN Labs and Sun Pharmaceutical — the only remaining generic-drug makers in a related consolidated case — infringe a patent issued Jan. 25 for the drug, used to treat irritable bowel syndrome with diarrhea.
[Read more: Allergan obtains FDA green light for Vuity]
Allergan’s settlements with Aurobindo Pharma and Zydus were recently approved in the U.S. District Court for the District of Delaware, leaving MSN and Sun as the only remaining defendants, according to a Bloomberg Law report.